CEO and Chairman of VitaSpring face multiple Taiwan legal proceedings including indictments

VITASPRING BIOMEDICAL CO. LTD.

CEO Kao and Chairman Chu involved in criminal civil cases for unauthorized IP use, violations of Taiwan's Pharmaceutical Affairs Act.
Chu and Kao indicted March 31 2025 under Pharmaceutical Affairs Act; court hearings June 2 2025, next set for Sept 22 2025.
TMU fiduciary duty case ongoing; NT$500M (approx $15.5M) civil damages claim against Chu and others.
In exosome case, Chu acquitted by Tainan District Court; prosecutor has appealed.
Company says it is not a named party and does not expect material adverse effect on operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.